Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. Marc S. Sabatine MD, MPH Eugene Braunwald MD. Journal of the American College of Cardiology. Volume 77, Issue 22, 8 June 2021, Pages 2822-2845. TIMI was honored to be included by JACC in their series of the best population research studies. Drs. Braunwald and Sabatine describe the origins of the TIMI Study Group, its many contributions over the years, and future directions.
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. K Oyama, RM Furtado, A Fagundes Jr, TA Zelniker, M Tang, J Kuder, SA Murphy, A Hamer, H Wang, AC Keech, RP Giugliano, MS Sabatine, BA Bergmark. J Am Coll Cardiol. 2021 Jan 26;77(3):259-267. doi: 10.1016/j.jacc.2020.11.011. Epub 2020 Nov 13. PCSK9 inhibitors have been shown to induce coronary plaque regression in small studies, but whether this effect would translate into a meaningful impact on coronary anatomic complexity in a large trial cohort was not known. In a post hoc analysis of the FOURIER trial, we found that evolocumab reduced the risk of complex coronary revascularization procedures, including complex PCI and CABG individually. These findings suggest that very aggressive LDL-C lowering may have beneficial effects on coronary atherosclerosis burden, anatomic complexity, and need for coronary revascularization.
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Circ G enom Precis Med. 2021 Jan 12. doi: 10.1161/CIRCGEN.120.003006. In a broad spectrum of patients with cardiometabolic disease, a polygenic risk score is a strong predictor of VTE identifying one-third of patients with a risk of VTE similar to patients with monogenic inherited thrombophilia.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. NA Marston, PN Patel, FK Kamanu, F Nordio, GM Melloni, C Roselli, Y Gurmu, L-C Weng, MP Bonaca, RP Giugliano, BM Scirica, ML O’Donoghue, CP Cannon, CD Anderson, DL Bhatt, PG Steg, M Cohen, RF Storey, P Sever, AC Keech, I Raz, O Mosenzon, EM Antman, E Braunwald, PT Ellinor, SA Lubitz, MS Sabatine, CT Ruff. Circulation. 2021 Feb 2;143(5):470-478. doi: 10.1161/CIRCULATIONAHA.120.051927. Epub 2020 Nov 13. Across 5 large clinical trials of subjects with cardiometabolic disease, a 32-SNP GRS was a strong, independent predictor of ischemic stroke. The predictive value of the GRS appeared strongest in subjects without previous stroke and in subjects with fewer clinical risk factors. Moreover, in patients with atrial fibrillation but lower CHA2DS2-VASc scores, the GRS identified patients with risk comparable to those with higher CHA2DS2-VASc scores.
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O’Donoghue ML. Circulation. 2021 Feb 16;143(7):685-695. doi: 10.1161/CIRCULATIONAHA.120.052339. It has long been recognized that women are underrepresented in clinical trials. However, few have examined the participation of women once successfully enrolled in a clinical trial. The current analysis examined rates of drug discontinuation and study retention in women versus men across cardiovascular outcome trials in an effort to better understand why women may be more apt to discontinue study participation once already enrolled. In turn, the findings may be informative so we can help ensure adequate support to encourage participation of women in future clinical trials.
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjöstrand M, Solomon SD, McMurray JJV, Sabatine MS. JAMA Cardiol. 2021 Feb 17. doi: 10.1001/jamacardio.2020.7585. In this analysis from the DAPA-HF trial, we showed that treatment with dapagliflozin was associated with a rapid reduction in risk of cardiovascular death or worsening heart failure in patients with heart failure with reduced ejection fraction (HFrEF), with particularly large absolute risk reductions in patients with a more recent HF hospitalization. These data highlight the opportunity for rapid clinical benefit when initiating dapagliflozin in patients with HFrEF.
The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. Lawler PR, Berg DD, Park JG, Katz JN, Baird-Zars VM, Barsness GW, Bohula EA, Carnicelli AP, Chaudhry SP, Jentzer JC, Menon V, Metkus T, Nativi-Nicolau J, Phreaner N, Sinha SS, Teuteberg JJ, van Diepen S, Morrow DA; Critical Care Cardiology Trials Network Investigators. Crit Care Med. 2021 Apr 2. doi: 10.1097/CCM.0000000000004948. In the Critical Care Cardiology Trials Network Registry, an investigator-initiated multicenter research collaboration among cardiac ICUs (CICUs) in North America, we studied 8,240 CICU admissions among whom ~24% had cardiogenic shock. Overall in-hospital mortality among patients with established cardiogenic shock was 39%; however, it was possible to identify clinical stages of shock for which mortality varied from only 15.8% to 32.1% to 62.5%. Using emerging clinical classification schemes, it is possible to identify a broad spectrum of risk among patients with cardiogenic shock.
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. TA Zelniker, DA Morrow, O Mosenzon, EL Goodrich, P Jarolim, SA Murphy, DL Bhatt, LA Leiter, DK McGuire, J Wilding, C Bode, BS Lewis, I Gause-Nilsson, AM Langkilde, M Fredriksson, I Raz, MS Sabatine, SD Wiviott. Eur J Heart Fail. 2021 Jun;23(6):1026-1036. doi: 10.1002/ejhf.2073. Epub 2020 Dec 29. In this large nested biomarker study from the DECLARE-TIMI 58 trial, we studied cardiovascular biomarkers of myocardial injury (hsTn) and hemodynamic stress (NTproBNP) in 14,565 patients with type 2 diabetes with and without atherosclerotic vascular disease. Patients with type 2 diabetes mellitus and higher NT-proBNP or hsTnT levels are were at significantly increased risk of cardiovascular death and heart failure. Dapagliflozin reduced the relative risk of CV death or heart failure irrespective of NT-proBNP and hsTnT levels, with greater absolute risk reductions seen in patients with higher baseline biomarker levels.
Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Marston NA, Oyama K, Jarolim P, Tang M, Sever PS, Keech AC, Lira Pineda A, Wang H, Giugliano RP, Sabatine MS, Morrow DA. Circulation. 2021 Jul 20;144(3):249-251. Among patients with ASCVD, either hsTn or ASCVD clinical criteria can identify patients who benefit from evolocumab. Specifically, hsTnI identifies a significant cohort of not very high-risk patients with ASCVD who are at greater risk than otherwise appreciated and derive risk reductions with evolocumab on par with clinically very high-risk patients with ASCVD.
Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl. Marston NA, Giugliano RP, Park JG, Ruzza A, Sever PS, Keech AC, Sabatine MS. Circulation. 2021 Aug 27. doi: 10.1161/CIRCULATIONAHA.121.056536. In this study from the FOURIER trial, lowering LDL-C below 40 mg/dL continued to provide cardiovascular benefit, supporting more aggressive treatment in a wider range of patients with ASCVD.
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DA. Diabetes Care. 2021 Sep 17:dc211170. doi: 10.2337/dc21-1170. Extending our previous work with clinical risk prediction, we developed and validated a biomarker-based score incorporating circulating biomarkers of myocardial injury (high-sensitivity troponin) and hemodynamic stress (NT-proBNP) to predict risk of hospitalization for heart failure (HF) in patients with type 2 diabetes using data from the SAVOR-TIMI 53 and DECLARE-TIMI 58 clinical trial databases. The score identifies patients who derive greater absolute treatment benefit from SGLT2 inhibitors, underscoring the potential value of biomarker-based cardiovascular risk stratification in type 2 diabetes.
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Ruff CT, Koren MJ, Grimsby J, Rosenbaum AI, Tu X, Karathanasis SK, Falloon J, Hsia J, Guan Y, Conway J, Tsai LF, Hummer BT, Hirshberg B, Kuder J, Murphy SA, George RT, Sabatine MS. Arterioscler Thromb Vasc Biol. 2021 Oct 28:ATVBAHA120315757. doi: 10.1161/ATVBAHA.120.315757. Inhibition of endothelial lipase with the selective, humanized, monoclonal antibody MEDI5884 increased the quantify and quality of functional HDL in patients with stable CAD on high-intensity statin therapy without an adverse safety signal. These data support further clinical investigation to determine whether inhibition of endothelial lipase prevents progression of atherosclerosis.
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Christiansen EH, Holm NR, Nielsen PH, Stone GW, Sabik JF, Braunwald E. Lancet. 2021 Nov 12:S0140-6736(21)02334-5. doi: 10.1016/S0140-6736(21)02334-5. Major society guidelines regarding revascularization for left main coronary artery disease with PCI using DES vs CABG stem principally from 4 major trials: SYNTAX, PRECOMBAT, NOBLE, and EXCEL. Differences in trial composite end points and interpretation have lead to ongoing uncertainty about the optimal revascularization strategy. In a collaboration between a group of independent investigators and the principal investigators of each trial, we performed an individual patient data meta-analysis using a combined dataset from all four trials. There was no statistically significant difference in mortality through 5 years, though a Bayesian analysis suggested that a mortality difference favoring CABG probably exists, and that the magnitude of this difference is more likely than not <0.2%/yr. There were trade-offs in terms of the risk of myocardial infarction, stroke, and revascularization, and these findings, which are anticipated to inform future revascularization guidelines, emphasize the importance of a heart team approach to communicate expected outcome differences to patients when discussing treatment options.
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, Ference B, Stein E, Stroes ES, Braunwald E, Ellinor PT, Lubitz SA, Ruff CT, Sabatine MS. JAMA Cardiol. 2021 Nov 13. doi: 10.1001/jamacardio.2021.5083. This study demonstrated the lipid-associated risk of MI was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich). This suggests that apoB may be the primary driver of atherosclerosis and that lowering the overall concentration of all apoB-containing lipoproteins should be the focus of therapeutic strategies.
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, de Boer RA, Kosiborod MN, Nicolau JC, O’Meara E, Schou M, Hammarstedt A, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJV, Sabatine MS, Morrow DA. Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057852. In this biomarker substudy of the DAPA-HF trial, we showed that higher baseline high-sensitivity cardiac troponin (hsTn) levels and greater increases in hsTn over 1 year are associated with worse clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Serial measurement of hsTn may provide objective assessment of clinical trajectory, which might in turn be used to inform clinical decision-making.
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Nat Med. 2021 Dec 6. doi: 10.1038/s41591-021-01584-3. In a pre-approval CV outcomes safety trial, sustained and continuous infusion of the GLP-1RA exenatide by an osmotic mini-pump (ITCA 650) met the FDA guidance for non-inferiority to placebo in a broad population of patients with T2D who had or were at risk for ASCVD. ITCA 650 also led to sustained reductions in glycated hemoglobin and weight loss with a similar safety profile to other GLP-1RAs. A larger and longer duration CV outcomes trial is needed to define more precisely the CV effects of ITCA 650.
Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. Bonaca MP, Antman EM, Cunningham JW, Wiviott SD, Murphy SA, Halperin JL, Weitz JI, Grosso MA, Lanz HJ, Braunwald E, Giugliano RP, Ruff CT. Eur Heart J Cardiovasc Pharmacother. 2021 Dec 28:pvab089. doi: 10.1093/ehjcvp/pvab089.
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Cardiovasc Comput Tomogr. 2021 Dec 1:S1934-5925(21)00469-X. doi: 10.1016/j.jcct.2021.11.009.
How to implement novel diagnostic algorithms for non-ST-segment elevation myocardial infarction in the emergency department. Cullen L, Mills NL, Morrow DA, Mueller C. Eur Heart J Acute Cardiovasc Care. 2021 Dec 18:zuab118. doi: 10.1093/ehjacc/zuab118.
N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort. O’Donnell C, Ashland MD, Vasti EC, Lu Y, Chang AY, Wang P, Daniels LB, de Lemos JA, Morrow DA, Rodriguez F, O’Brien CG. J Am Heart Assoc. 2021 Dec 10:e022913. doi: 10.1161/JAHA.121.022913.
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJL; DAPA-CKD and DAPA-HF Trial Committees and Investigators. Lancet Diabetes Endocrinol. 2021 Nov 29:S2213-8587(21)00295-3. doi: 10.1016/S2213-8587(21)00295-3.
Exploring patient experiences coping with using multiple medications: a qualitative interview study. Lauffenburger JC, Haff N, McDonnell ME, Solomon DH, Antman EM, Glynn RJ, Choudhry NK. BMJ Open. 2021 Nov 22;11(11):e046860. doi: 10.1136/bmjopen-2020-046860.
Electronic Alerts to Initiate Anticoagulation Dialogue in Patients with Atrial Fibrillation. Antonio Gutierrez J, Ruff CT, Aday AW, Gu L, Schulteis RD, Shihai L, Petrini Pa-C M, Sun AY, Swaminathan RV, Katzenberger DR, Banerjee S, Rao SV. Am Heart J. 2021 Nov 19:S0002-8703(21)00452-X. doi: 10.1016/j.ahj.2021.11.008.
Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. Proudfoot AG, Kalakoutas A, Meade S, Griffiths MJD, Basir M, Burzotta F, Chih S, Fan E, Haft J, Ibrahim N, Kruit N, Lim HS, Morrow DA, Nakata J, Price S, Rosner C, Roswell R, Samaan MA, Samsky MD, Thiele H, Truesdell AG, van Diepen S, Voeltz MD, Irving PM. Circ Heart Fail. 2021 Nov 22. doi: 10.1161/CIRCHEARTFAILURE.121.008635.
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV, Køber L. Circ Heart Fail. 2021 Nov 22:CIRCHEARTFAILURE121008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837.
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). Aoki Y, Hamrén B, Clegg LE, Stahre C, Bhatt DL, Raz I, Scirica BM, Oscarsson J, Carlsson B. PLoS One. 2021 Nov 19;16(11):e0259372. doi: 10.1371/journal.pone.0259372. eCollection 2021.
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, Fernandez A, Filippatos G, Jering K, Landmesser U, Menon V, Prof Merkely B, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Wang Y, Braunwald E. Circulation. 2021 Nov 19. doi: 10.1161/CIRCULATIONAHA.121.057429.
The European Heart Journal Acute Cardiovascular Care (EHJ ACVC) 2022: message from the editorial board. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2021 Nov 10:zuab101. doi: 10.1093/ehjacc/zuab101.
Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Varshney AS, Omar WA, Goodrich EL, Bhatt AS, Wolley AE, Gong J, Senman BC, Silva D, Levangie MW, Berg DD, Yeh RW, de Lemos JA, Morrow DA, Kazi DS, Bohula EA. Circ Heart Fail. 2021 Nov 18: CIRCHEARTFAILURE121008477. doi: 10.1161/CIRCHEARTFAILURE.121.008477.
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF. Butt JH, Docherty KF, Jhund PS, De Boer RA, Böhm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC, Petrie MC, Ponikowski P, Bengtsson O, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, McMurray JJ, Køber L. Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.
Workflow Automation for a Virtual Hypertension Management Program. Gordon WJ, Blood AJ, Chaney K, Clark E, Glynn C, Green R, Laurent JS, Mailly C, McPartlin M, Murphy S, Nichols H, Oates M, Subramaniam S, Varugheese M, Wagholikar K, Aronson S, Scirica BM. Appl Clin Inform. 2021 Oct;12(5):1041-1048. doi: 10.1055/s-0041-1739195. Epub 2021 Nov 10.
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508.
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Am Coll Cardiol. 2021 Oct 23:S0735-1097(21)05795-8. doi: 10.1016/j.jacc.2021.07.053.
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Am Coll Cardiol. 2021 Oct 23:S0735-1097(21)05794-6. doi: 10.1016/j.jacc.2021.07.052.
Cardiogenic Shock After Acute Myocardial Infarction: A Review. Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. JAMA. 2021 Nov 9;326(18):1840-1850. doi: 10.1001/jama.2021.18323.
SGLT2 inhibitors: the statins of the 21st century. Braunwald E. Eur Heart J. 2021 Nov 6:ehab765. doi: 10.1093/eurheartj/ehab765.
Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. Berg DD, Kolkailah AA, Sarraju A, Kerchberger AM, Eljalby M, McGuire DK.
Curr Diab Rep. 2021 Nov 6;21(11):45. doi: 10.1007/s11892-021-01417-0.
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. JAMA Cardiol. 2021 Nov 3. doi: 10.1001/jamacardio.2021.4567.
High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. David D Berg, Marc S Sabatine, Naveed Sattar, Petr Jarolim, Paul WELSH, Pardeep S Jhund, Inder Anand, Rudolf A De Boer, Mikhail Kosiborod, Eileen O’Meara, Ann Hammarstedt, Anna Maria Langkilde, Daniel Lindholm, Mikaela Sjöstrand, John J McMurray, David Morrow. Originally published 8 Nov 2021Circulation. 2021;144:A11692.
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Circulation. 2021 Oct 28. doi: 10.1161/CIRCULATIONAHA.121.056290.
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. Circulation. 2021 Oct 28:CIR0000000000001030. doi: 10.1161/CIR.0000000000001030.
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. Circulation. 2021 Oct 28:CIR0000000000001029. doi: 10.1161/CIR.0000000000001029.
Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D, Gil EG. Respir Res. 2021 Oct 22;22(1):272. doi: 10.1186/s12931-021-01861-2.
Improving prediction of anticoagulant-related major bleeding in atrial fibrillation: The search for new biomarkers. Berg DD, Morrow DA. J Thromb Haemost. 2021 Nov;19(11):2674-2676. doi: 10.1111/jth.15525.
Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention. Paruchuri K, Finneran P, Marston NA, Healy EW, Andreo J Jr, Lynch R, Blood AJ, Jones-O’Connor M, Lander B, Kelly N, Vivaldi MT, Traynor K, Wiviott S, Natarajan P. EBioMedicine. 2021 Sep 15:103593. doi: 10.1016/j.ebiom.2021.103593.
In Memoriam: A Tribute to Attilio Maseri. Crea F, Braunwald E, Fuster V. J Am Coll Cardiol. 2021 Oct 7:S0735-1097(21)07176-X. doi: 10.1016/j.jacc.2021.10.001.
Digital health device measured sleep duration and ideal cardiovascular health: an observational study. Leopold JA, Antman EM. BMC Cardiovasc Disord. 2021 Oct 14;21(1):497. doi: 10.1186/s12872-021-02284-z.
A tribute to Attilio Maseri. Crea F, Braunwald E, Fuster V. Eur Heart J. 2021 Oct 12:ehab714. doi: 10.1093/eurheartj/ehab714.
Cardiac myosin-binding protein C as a biomarker of acute myocardial infarction. Marber MS, Mills NL, Morrow DA, Mueller C. Eur Heart J Acute Cardiovasc Care. 2021 Oct 11:zuab086. doi: 10.1093/ehjacc/zuab086.
Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. Figueroa JM, Lombardo ME, Dogliotti A, Flynn LP, Giugliano R, Simonelli G, Valentini R, Ramos A, Romano P, Marcote M, Michelini A, Salvado A, Sykora E, Kniz C, Kobelinsky M, Salzberg DM, Jerusalinsky D, Uchitel O. Int J Gen Med. 2021 Oct 1;14:6277-6286. doi: 10.2147/IJGM.S328486.
Closing the Gap: Insights into the Epidemiology of Heart Failure Care from the Critical Care Cardiology Trials Network. Morrow DA. J Card Fail. 2021 Oct;27(10):1146-1147.
De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. Bhatt AS, Berg DD, Bohula EA, Alviar CL, Baird-Zars VM, Barnett CF, Burke JA, Carnicelli AP, Chaudhry SP, Daniels LB, Fang JC, Fordyce CB, Gerber DA, Guo J, Jentzer JC, Katz JN, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Nativi-Nicolau J, Phreaner N, Roswell RO, Sinha SS, Jeffrey Snell R, Solomon MA, Van Diepen S, Morrow DA. J Card Fail. 2021 Oct;27(10):1073-1081.
The Nexus of Heart Failure and Critical Care Cardiology. Sinha SS, Bohula EA, Katz JN. J Card Fail. 2021 Oct;27(10):1041.
Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. Gilchrist IC Jr, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. J Am Heart Assoc. 2021 Oct 8:e021412.
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Gaba P, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Ballantyne CM, Pinto DS, Budoff MJ, Gibson CM.J Am Coll Cardiol. 2021 Oct 12;78(15):1525-1537.
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald E. J Am Coll Cardiol. 2021 Oct 12;78(15):1499-1507.
Heart failure with preserved ejection fraction: a stepchild no more! Braunwald E. Eur Heart J. 2021 Oct 7;42(38):3900-3901.
Risk factors for type 2 MI: the usual suspects or guilt by association? O’Donoghue ML, Marston NA. Eur Heart J. 2021 Oct 2:ehab707. doi: 10.1093/eurheartj/ehab707.
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators, Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Nat Med. 2021 Sep 23. doi: 10.1038/s41591-021-01505-4.
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. Papolos AI, Kenigsberg BB, Berg DD, Alviar CL, Bohula E, Burke JA, Carnicelli AP, Chaudhry SP, Drakos S, Gerber DA, Guo J, Horowitz JM, Katz JN, Keeley EC, Metkus TS, Nativi-Nicolau J, Snell JR, Sinha SS, Tymchak WJ, Van Diepen S, Morrow DA, Barnett CF; Critical Care Cardiology Trials Network Investigators. J Am Coll Cardiol. 2021 Sep 28;78(13):1309-1317. doi: 10.1016/j.jacc.2021.07.044.
Walking the tightrope between ischaemia and bleeding. O’Donoghue ML, Patel SM. EuroIntervention. 2021 Sep 20;17(7):527-529. doi: 10.4244/EIJV17I7A93.
Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Chuecos F, Garcia Gil E, Chapman KR. Adv Ther. 2021 Sep 15. doi: 10.1007/s12325-021-01878-5.
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Kazuma Oyama, Robert P Giugliano, Minao Tang, Marc P Bonaca, Jeffrey L Saver, Sabina A Murphy, Andrea Ruzza, Anthony C Keech, Peter S Sever, Marc S Sabatine, Brian A Bergmark. Eur Heart J. 2021 Sept 19; ehab604. doi: 10.1093/eurheartj/ehab604.
Inhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction – Findings from the LATITUDE TIMI 60 Trial. Cavender MA, O’Donoghue M, Abbate A, Aylward P, Fox KAA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Am Heart J. 2021 Sep 8:S0002-8703(21)00229-5. doi: 10.1016/j.ahj.2021.08.022.
Population Health Identification and Management of Low Density Lipoprotein Cholesterol via a Remote, Algorithmic, Navigator-Executed Program. Plutzky J, Benson MD, Chaney K, Bui TV, Kraft M, Matta L, McPartlin M, Zelle D, Cannon CP, Dodek A, Gaziano TA, Desai AS, MacRae CA, Scirica BM. Am Heart J. 2021 Sep 2:S0002-8703(21)00223-4. doi: 10.1016/j.ahj.2021.08.017.
The genomics of heart failure: design and rationale of the HERMES consortium. Lumbers RT, Shah S, Lin H, Czuba T, Henry A, Swerdlow DI, Mälarstig A, Andersson C, Verweij N, Holmes MV, Ärnlöv J, Svensson P, Hemingway H, Sallah N, Almgren P, Aragam KG, Asselin G, Backman JD, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunner-La Rocca HP, Carey DJ, Chaffin MD, Chasman DI, Chazara O, Chen X, Chen X, Chung JH, Chutkow W, Cleland JGF, Cook JP, de Denus S, Dehghan A, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Engström G, Esko T, Fatemifar G, Felix SB, Finan C, Ford I, Fougerousse F, Fouodjio R, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gui H, Gutmann R, Haggerty CM, van der Harst P, Hedman ÅK, Helgadottir A, Hillege H, Hyde CL, Jacob J, Jukema JW, Kamanu F, Kardys I, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Kraus B, Kuchenbaecker K, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Mann D, Margulies KB, Marston NA, März W, McMurray JJV, Melander O, Melloni G, Mordi IR, Morley MP, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Newton-Cheh C, Niessner A, Niiranen T, Nowak C, O’Donoghue ML, Owens AT, Palmer CNA, Paré G, Perola M, Perreault LL, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Roselli C, Rotter JI, Ruff CT, Sabatine MS, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stefansson K, Stender S, Stott DJ, Sveinbjörnsson G, Tammesoo ML, Tardif JC, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tuckwell D, Tyl B, Uitterlinden AG, Vaura F, Veluchamy A, Visscher PM, Völker U, Voors AA, Wang X, Wareham NJ, Weeke PE, Weiss R, White HD, Wiggins KL, Xing H, Yang J, Yang Y, Yerges-Armstrong LM, Yu B, Zannad F, Zhao F; Regeneron Genetics Center, Wilk JB, Holm H, Sattar N, Lubitz SA, Lanfear DE, Shah S, Dunn ME, Wells QS, Asselbergs FW, Hingorani AD, Dubé MP, Samani NJ, Lang CC, Cappola TP, Ellinor PT, Vasan RS, Smith JG. ESC Heart Fail. 2021 Sep 3. doi: 10.1002/ehf2.13517.
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV. Eur Heart J. 2021 Aug 27:ehab560. doi: 10.1093/eurheartj/ehab560.
A new initiative of the European Heart Journal: the Desmond Julian Award. Crea F, Braunwald E. Eur Heart J. 2021 Aug 26:ehab535. doi: 10.1093/eurheartj/ehab535.
Assessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. Marcusa DP, Giugliano RP, Sabatine MS. JAMA Cardiol. 2021 Aug 25. doi: 10.1001/jamacardio.2021.3028.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Eur Heart J. 2021 Aug 24:ehab530. doi: 10.1093/eurheartj/ehab530.
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. J Am Heart Assoc. 2021 Aug 21:e020446. doi: 10.1161/JAHA.120.020446.
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. Giugliano RP, Gencer B, Wiviott SD, Park JG, Fuchs CS, Goessling W, Musliner TA, Tershakovec AM, Blazing MA, Califf R, Cannon CP, Braunwald E. JACC CardioOncol. 2020 Sep 15;2(3):385-396. doi: 10.1016/j.jaccao.2020.07.008. eCollection 2020 Sep.
Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives. Cho L, Vest AR, O’Donoghue ML, Ogunniyi MO, Sarma AA, Denby KJ, Lau ES, Poole JE, Lindley KJ, Mehran R; Cardiovascular Disease in Women Committee Leadership Council. J Am Coll Cardiol. 2021 Aug 17;78(7):737-751.
An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. Antman EM, Freeman MW, Golan DE, Kitterman R, McKenna E, Parrish J, Vaughan C, Watts L, Loscalzo J. J Clin Transl Sci. 2021 May 17;5(1):e137.
Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. Colaco NA, Wang TS, Ma Y, Scherzer R, Ilkayeva OR, Desvigne-Nickens P, Braunwald E, Hernandez AF, Butler J, Shah SH, Shah SJ, Hsue PY. J Am Heart Assoc. 2021 Aug 7:e020499. doi: 10.1161/JAHA.120.020499.
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. Berg DD, Giugliano RP, Ruff CT, Tang M, Im K, Jarolim P, Rutman H, Antman EM, Braunwald E, Morrow DA. J Am Coll Cardiol. 2021 Aug 10;78(6):634-636. doi: 10.1016/j.jacc.2021.06.008.
How to live to 100 before developing clinical coronary artery disease: a suggestion. Braunwald E. Eur Heart J. 2021 Aug 6:ehab532. doi: 10.1093/eurheartj/ehab532.
Cholesterol: the race to the bottom. Braunwald E. Eur Heart J. 2021 Aug 2:ehab446. doi: 10.1093/eurheartj/ehab446.
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. JAMA Cardiol. 2021 Jul 28. doi: 10.1001/jamacardio.2021.2632.
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O’Donoghue ML. Eur J Prev Cardiol. 2021 Jul 23;28(8):805-812.
A precision medicine approach to sex-based differences in ideal cardiovascular health. Leopold JA, Antman EM. Sci Rep. 2021 Jul 21;11(1):14848.
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang CE, Diez M, Drożdż J, Dukát A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJ. Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
Early Aspirin Use, Allograft Rejection, and Cardiac Allograft Vasculopathy in Heart Transplantation. Bergmark BA, Zelniker TA, Kim M, Mehra MR, Stewart GC, Page DS, Woodcome EL, Givertz MM. Clin Transplant. 2021 Jul 13. doi: 10.1111/ctr.14424.
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. Diabetes Care. 2021 Jul 7:dc210076. doi: 10.2337/dc21-0076.
Ideal Cardiovascular Health in Former Smokers. Leopold JA, Antman EM. J Clin Med. 2021 Jun 1;10(11):2450. doi: 10.3390/jcm10112450.
Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? Steffel J, Ruff CT, Antman EM, Braunwald E, Giugliano RP. J Am Coll Cardiol. 2021 Jun 29;77(25):3232-3233.
Myocardial Infarction and Evolocumab-Reply. Wiviott SD, Giugliano RP, Sabatine MS. JAMA Cardiol. 2021 Jun 23. doi: 10.1001/jamacardio.2021.2000
Reflections on Hypertrophic Cardiomyopathy. Braunwald E. Eur Heart J. 2021 Jun 21:ehab337. doi: 10.1093/eurheartj/ehab337.
Platelet Reactivity and Coagulation Markers in Patients with COVID-19. Bertolin AJ, Dalçóquio TF, Salsoso R, de M Furtado RH, Kalil-Filho R, Hajjar LA, Siciliano RF, Kallás EG, Baracioli LM, Lima FG, Giraldez RR, Cavalheiro-Filho C, Vieira A, Strunz CMC, Giugliano RP, Tantry US, Gurbel PA, Nicolau JC. Adv Ther. 2021 Jun 4. doi: 10.1007/s12325-021-01803-w.
Hypertensive Heartbreak. Lau ES, Scirica B, Schaefer IM, Miller AL, Loscalzo J. N Engl J Med. 2021 Jun 3;384(22):2145-2152. doi: 10.1056/NEJMcps2018493.
Hypertensive Heartbreak. Lau ES, Vaidya A, Schaefer IM, Scirica BM. N Engl J Med. 2021 May 27;384(21):e80. doi: 10.1056/NEJMimc2031595.
Transseptal left heart catheterization: birth, death, and resurrection. Braunwald E. Eur Heart J. 2021 May 25:ehab264. doi: 10.1093/eurheartj/ehab264.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects – A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS; FOURIER Study Group. Circ J. 2021 May 12. doi: 10.1253/circj.CJ-20-1051.
Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. Roth GA, Emmons-Bell S, Alger HM, Bradley SM, Das SR, de Lemos JA, Gakidou E, Elkind MSV, Hay S, Hall JL, Johnson CO, Morrow DA, Rodriguez F, Rutan C, Shakil S, Sorensen R, Stevens L, Wang TY, Walchok J, Williams J, Murray C. JAMA Netw Open. 2021 May 3;4(5):e218828. doi: 10.1001/jamanetworkopen.2021.8828.
Initial Findings From the North American COVID-19 Myocardial Infarction Registry. Garcia S, Dehghani P, Grines C, Davidson L, Nayak KR, Saw J, Waksman R, Blair J, Akshay B, Garberich R, Schmidt C, Ly HQ, Sharkey S, Mercado N, Alfonso CE, Misumida N, Acharya D, Madan M, Hafiz AM, Javed N, Shavadia J, Stone J, Alraies MC, Htun W, Downey W, Bergmark BA, Ebinger J, Alyousef T, Khalili H, Hwang CW, Purow J, Llanos A, McGrath B, Tannenbaum M, Resar J, Bagur R, Cox-Alomar P, Stefanescu Schmidt AC, Cilia LA, Jaffer FA, Gharacholou M, Salinger M, Case B, Kabour A, Dai X, Elkhateeb O, Kobayashi T, Kim HH, Roumia M, Aguirre FV, Rade J, Chong AY, Hall HM, Amlani S, Bagherli A, Patel RAG, Wood DA, Welt FG, Giri J, Mahmud E, Henry TD; Society for Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council. J Am Coll Cardiol. 2021 Apr 27;77(16):1994-2003. doi: 10.1016/j.jacc.2021.02.055.
Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. J Am Heart Assoc. 2021 Apr 22:e018673. doi: 10.1161/JAHA.120.018673.
Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science. Sabatine MS. JAMA Cardiol. 2021 Apr 21. doi: 10.1001/jamacardio.2021.0693.
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. JAMA Cardiol. 2021 Apr 14. doi: 10.1001/jamacardio.2021.0660.
Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics. Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, Guo W, Zhou Y, Lefkowitz M, Gong J, Wang Y, Merkely B, Macin SM, Shah U, Nicolau JC, Braunwald E. Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. Zelniker TA, Morrow DA, Scirica BM, Furtado JD, Guo J, Mozaffarian D, Sabatine MS, O’Donoghue ML. J Am Heart Assoc. 2021 Apr 12:e017401. doi: 10.1161/JAHA.120.017401.
Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement. Churchwell K, Antman E, Birnbaum J, Desai NR, Harrington RA, Holubowich EJ, Ivy KN, Schoeberl M, Warner JJ, White CJ, Whitsel LP, Yancy C; American Heart Association Advocacy Coordinating Committee. Circulation. 2021 Apr 12:CIR0000000000000972. doi: 10.1161/CIR.0000000000000972.
Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. Cavallari I, Bhatt DL, Steg PG, Leiter LA, McGuire DK, Mosenzon O, Im K, Raz I, Braunwald E, Scirica BM. J Am Coll Cardiol. 2021 Apr 13;77(14):1837-1840. doi: 10.1016/j.jacc.2021.02.030.
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF. Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Circulation. 2021 Apr 9. doi: 10.1161/CIRCULATIONAHA.121.053659.
Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. Smith KV, Dunning JR, Fischer CM, MacLean TE, Bosque-Hamilton JW, Fera LE, Grant JY, Zelle DJ, Matta L, Gaziano TA, MacRae CA, Scirica BM, Desai AS. J Pharm Pract. 2021 Apr 5:8971900211004840. doi: 10.1177/08971900211004840.
Data from Digital Health Devices Informs Ideal Cardiovascular Health. Leopold JA, Davis RB, Antman EM. J Pers Med. 2021 Mar 10;11(3):189. doi: 10.3390/jpm11030189.
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O’Meara E, Katova T, Ljungman CEA, Diez M, Ogunniyi MO, Langkilde AM, Sjöstrand M, Lindholm D, Bengtsson O, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Jhund PS, McMurray JJV, Køber L. JAMA Cardiol. 2021 Mar 31. doi: 10.1001/jamacardio.2021.0379.
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. Wise RA, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D, Garcia-Gil E. Int J Chron Obstruct Pulmon Dis. 2021 Mar 18;16:689-699. doi: 10.2147/COPD.S285068.
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, Pereira AC, Ingles J, Semsarian C, Jacoby D, Colan SD, Rossano JW, Wittekind SG, Ware JS, Saberi S, Helms AS, Ho CY. Eur Heart J. 2021 Mar 26:ehab148. doi: 10.1093/eurheartj/ehab148.
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Oyama K, Giugliano RP, Berg DD, Ruff CT, Jarolim P, Tang M, Murphy SA, Lanz HJ, Grosso MA, Antman EM, Braunwald E, Morrow DA. Eur Heart J. 2021 Mar 24:ehab141. doi: 10.1093/eurheartj/ehab141.
SPOT the DIAGNOSIS. Verbrugge FH, Morrow DA, Vranckx P. Eur Heart J Acute Cardiovasc Care. 2021 Mar 24:zuab011. doi: 10.1093/ehjacc/zuab011.
Trends in Therapy and Outcomes Associated With Respiratory Failure in Patients Admitted to the Cardiac Intensive Care Unit. Jentzer JC, Alviar CL, Miller PE, Metkus T, Bennett CE, Morrow DA, Barsness GW, Kashani KB, Gajic O. J Intensive Care Med. 2021 Mar 24:8850666211003489. doi: 10.1177/08850666211003489.
Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. Ravvaz K, Weissert JA, Jahangir A, Ruff CT. PLoS One. 2021 Mar 18;16(3):e0248134. doi: 10.1371/journal.pone.0248134. eCollection 2021.
The Birth of Cardiology: The Golden Decade. Braunwald E. Eur Heart J. 2021 Mar 10:ehab119. doi: 10.1093/eurheartj/ehab119.
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Steffel J, Ruff CT, Yin O, Braunwald E, Park JG, Murphy SA, Connolly S, Antman EM, Giugliano RP. J Am Coll Cardiol. 2021 Mar 9;77(9):1197-1207.
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD. Diabetes Care. 2021 Mar 2:dc202492. doi: 10.2337/dc20-2492.
Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”. Giugliano RP, De Caterina R, Yamashita T. Drug Saf. 2021 Feb 24. doi: 10.1007/s40264-021-01055-1.
Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Gencer B, Morrow DA, Braunwald E, Goodrich EL, Hilvo M, Kauhanen D, Sabatine MS, Laaksonen R, O’Donoghue ML. Eur J Prev Cardiol. 2020 Dec 29:zwaa143. doi: 10.1093/eurjpc/zwaa143.
Effect of dapagliflozin on anaemia in DAPA-HF. Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Eur J Heart Fail. 2021 Feb 22. doi: 10.1002/ejhf.2132.
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. O’Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD. Diabetologia. 2021 Feb 20. doi: 10.1007/s00125-021-05399-2.
Incidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction. Metkus T, Miller PE, Alviar CL, Jentzer JC, van Diepen S, Katz JN, Morrow DA, Schulman S, Eid S. Eur Heart J Acute Cardiovasc Care. 2020 Apr 23:2048872620919947. doi: 10.1177/2048872620919947.
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20:2048872619896205. doi: 10.1177/2048872619896205.
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF Trial. Nassif ME, Windsor SL, Tang F, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Fong MW, LaRue SJ, Umpierrez G, Hartupee J, Khariton Y, Malik AO, Ogunniyi MO, Wenger NK, Kosiborod MN. Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14352.
The Path to Universality. Braunwald E, Antman EM. Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2129.
Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Patel PN, Giugliano RP. Glob Cardiol Sci Pract. 2020 Dec 31;2020(3):e202039. doi: 10.21542/gcsp.2020.39.
Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial. Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Bengtsson O, Jhund PS, McMurray JJV, Køber L. Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Zelniker TA, Ardissino M, Andreotti F, O’Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA. Circulation. 2021 Feb 16;143(7):673-684. doi: 10.1161/CIRCULATIONAHA.120.052216.
Potential growth in cardiogenic shock research though an international registry collaboration: the merits and challenges of a Hub-of-Spokes model. van Diepen S, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2021 Jan 4:zuaa038. doi: 10.1093/ehjacc/zuaa038.
Learning and innovation among interventional cardiologists: Insights from an international survey. Vemmou E, Nikolakopoulos I, Xenogiannis I, Karacsonyi J, Rangan BV, Garcia S, Burke MN, Jneid H, Croce KJ, Bergmark BA, Brilakis ES. Catheter Cardiovasc Interv. 2021 Feb 10. doi: 10.1002/ccd.29548.
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. J Am Heart Assoc. 2021 Feb 9:e017008. doi: 10.1161/JAHA.120.017008.
Comprehensive characterization of protein-protein interactions perturbed by disease mutations. Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y, Martin WR, Wang R, Huang J, Hao T, Yue H, Ma J, Hou Y, Castrillon JA, Fang J, Lathia JD, Keri RA, Lightstone FC, Antman EM, Rabadan R, Hill DE, Eng C, Vidal M, Loscalzo J. Nat Genet. 2021 Feb 8. doi: 10.1038/s41588-020-00774-y.
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez MFA, O’Meara E, Nicolau JC, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV. JACC Heart Fail. 2021 Jan 28:S2213-1779(20)30704-6. doi: 10.1016/j.jchf.2020.11.009.
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Circ Heart Fail. 2021 Feb 3:CIRCHEARTFAILURE120007034. doi: 10.1161/CIRCHEARTFAILURE.120.007034.
Cardiology in 2021. Braunwald E. Eur Heart J. 2021 Feb 2:ehab025. doi: 10.1093/eurheartj/ehab025.
Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG; TAO investigators. Arch Cardiovasc Dis. 2021 Jan 28:S1875-2136(21)00004-8. doi: 10.1016/j.acvd.2020.09.005.
Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment. Ting C, Rhoten M, Dempsey J, Nichols H, Fanikos J, Ruff CT. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620987900. doi: 10.1177/1076029620987900.
Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study. de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, Grip L, Lanz H, Mercuri MF, Antman EM, Giugliano R. Am Heart J. 2021 Jan 22:S0002-8703(21)00017-X. doi: 10.1016/j.ahj.2021.01.013.
Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. Bonaca MP, George RT, Morrow DA, Bergmark BA, Park JG, Abuhatzira L, Vavere AL, Karathanasis SK, Jin C, She D, Hirshberg B, Hsia J, Sabatine MS. Eur Heart J Cardiovasc Pharmacother. 2021 Jan 25:pvab001. doi: 10.1093/ehjcvp/pvab001.
Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Baris Gencer, David A Morrow, Eugene Braunwald, Erica L Goodrich, Mika Hilvo, Dimple Kauhanen, Marc S Sabatine, Reijo Laaksonen, Michelle L O’Donoghue. European Journal of Preventive Cardiology, https://doi.org/10.1093/eurjpc/zwaa143. Published: 29 December 2020.
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Nelson SE, Giugliano RP, Antman EM, Park JG, Norden AD, Rost NS, Silverman S, Singhal AB, Lanz HJ, Braunwald E, Ruff CT; ENGAGE AF-TIMI 48 Steering Committee and Investigators. J Clin Neurosci. 2021 Jan 11:S0967-5868(20)31595-2. doi: 10.1016/j.jocn.2020.10.036.
Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C Jr, Petrauskiene B, Henry P, Dorobantu M, French WJ, Wiviott SD, Sabatine MS, Mehta SR, Steg PG. Circ Cardiovasc Interv. 2021 Jan 12:CIRCINTERVENTIONS120009759. doi: 10.1161/CIRCINTERVENTIONS.120.009759.
Letter to the editor re: ‘serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review’. Sabatine MS, Giugliano RP, Schwartz GG. Expert Rev Clin Pharmacol. 2021 Jan 12:1-2. doi: 10.1080/17512433.2021.1874346.
Cardiac troponin elevation after elective PCI: adding infarct to major injury. Bergmark BA, Morrow DA. Eur Heart J. 2021 Jan 7:ehaa983. doi: 10.1093/eurheartj/ehaa983.